Medpace Holdings（MEDP） · Pharma Outsourcing (CRO)

Medpace Holdings Zen Horizon Framework Deep-Dive Research

Jun 6, 2026·~21 min read

Quick ReadPlain-language overview · read this first

Medpace is a U.S. company that helps pharmaceutical companies run clinical trials for new drugs. The report’s stance is “Watch”: this is a good business, but at this price and at this point in the cycle, it is not worth chasing. The suggestion is to put it on the watchlist and wait for a better opportunity.

What does it mainly do? Drug developers need to run extensive human trials when developing new medicines, and the process is complicated. Many small and midsize drug companies cannot do this themselves, so they outsource the full package to Medpace. About 80% of its clients are these smaller drug companies that rely on financing, so whether drug companies can raise money directly determines the temperature of Medpace’s business.

The business itself is quite solid: the founder owns a large stake, the company has no external debt at all, it still has surplus cash on hand, and revenue has compounded at about 22% per year over the past nine years. The report has almost no objection to the quality of the business.

So why only “Watch”? The core issue is cooling new orders. There is a metric that measures order momentum, with 1.0 as the expansion/contraction line. It has fallen for three straight quarters from 1.20 to 1.04 and then to 0.88, dropping below that line for the first time, and management also unusually admitted that growth over the next six months is a real issue. Yet the current share price is still priced for high growth and is much more expensive than peers, which means it is both expensive and offers no room to be wrong and still come out okay. The report therefore says the current price of $454 is expensive; the ideal buy price would be below $380, or investors should wait until order intake moves back above the expansion/contraction line and confirms a recovery before considering it.

The above is only a plain-language explanation of this report, not investment advice. The stock market involves risk; invest with caution.

Lead
Medpace Holdings is one of the leading U.S. full-service clinical CROs, focused on small and mid-sized biotech clients, founder-controlled, debt-free, and an exceptional high-ROIC compounder. The core thesis is that business quality remains outstanding, but current valuation, weakening leading indicators, and biotech funding-cycle exposure leave little margin of safety. Research rating Watch: a high-quality compounder worth monitoring, with a better entry point likely below $380 or after book-to-bill recovers above 1.0x.

Full report

Prices in the article are as of publication; see the valuation band above for the live price.

Research Perspective Statement

Subject: Medpace Holdings, Inc. (NASDAQ: MEDP), a Cincinnati-based full-service clinical contract research organization (CRO). ⚠️ Do not confuse it with Medicilon (688202.SHG, a China CRO). This report covers MEDP.US; the two are entirely different companies. A prior project topic file mislabeled MEDP as Medicilon, and this report corrects that error.
Currency: U.S. dollars (USD). Fiscal year: Calendar year, ending December 31.
Price anchor: All relative valuation in this report is based on the 2026-06-05 closing price of $454.25 (NASDAQ, −0.97% that day), market cap of about $12.97B, shares outstanding of about 28.56M, trailing PE of about 28.6x, forward PE of about 26x, and a 52-week range of $293.20 – $628.92 (down about 27.8% from the high, and far above the low). The price was cross-checked across stockanalysis.com, EODHD real-time data, and WebSearch, with consistent results (stockanalysis).
Data basis: Financial data are based on the company's primary SEC filings (FY2025 10-K, Q1'26 10-Q, quarterly 8-Ks, and DEF 14A 2026); industry, peer, and share-price data are cross-checked against authoritative secondary sources. Key accounting note: Since adopting ASC 606 in 2018, Medpace reports income-statement revenue under the gross method, including reimbursed costs. It is not directly comparable with pre-2018 net service revenue or with some peer reporting bases (see Section 4).

1. Conclusion First

Rating: Watch. Ideal buy price ≤ $380 (roughly 22x forward PE, about −16% below the current price).

Medpace is a genuinely high-quality business. That part is not in dispute: founder-controlled, debt-free, net cash, extremely high ROIC, about 22% organic revenue CAGR over the past nine years, and a compounding machine that has steadily reduced its share count through buybacks. The issue is not business quality. It is the current price and timing. The Watch rating, rather than Buy or Hold, rests on four independent reasons:

Leading indicators have deteriorated for three consecutive quarters and have fallen below the expansion/contraction line for the first time. Net book-to-bill moved from 1.20x (Q3'25) to 1.04x (Q4'25) to 0.88x (Q1'26). Cancellations reached a more-than-one-year high, RFP volume declined both sequentially and year over year, and backlog coverage fell for a sixth straight quarter. Management unusually acknowledged on the earnings call that “future six-month sequential growth is a real issue” and that there are “things to worry about” (Q1'26 call). This is the core reason the market marked the stock down despite two consecutive quarters of revenue and EPS beats. The market is pricing future deceleration, not a current-period miss.
Reported growth is amplified by accounting presentation, while underlying momentum is weaker. Within Q1'26 reported revenue growth of +26.5%, zero-margin reimbursed costs increased +54.1% year over year, while underlying direct service costs increased only +11.5%. Reimbursed costs as a share of revenue have risen from 38.3% in FY2023 to 44.2% in Q1'26 (Q1'26 10-Q). Real service-business growth is far lower than the headline number.
Valuation is full, with no margin of safety. The current price implies 28.6x trailing PE / about 26x forward PE / about 21x EV/EBITDA, a premium of +25% (trailing) to +65-85% (forward) versus CRO peers. Meanwhile, FY2026 revenue-growth guidance has slowed sharply from +20.0% in 2025 to +8.9%-12.8%. Sell-side consensus has fallen to Hold, with an average target of about $443, essentially in line with the current price (stockanalysis forecast). The premium is justified by quality, but not by today's combination of deceleration and cyclical exposure.
Governance and capital-allocation signals are adding negatives. ① A securities-fraud class action is pending (Durbin v. Medpace, class period 2025-04-22 to 2026-02-09), alleging management dressed up worsening cancellation trends as “very well behaved,” with lead-plaintiff deadline on 2026-06-08; ② after the share price fell below $600, the company cut buybacks to zero (Q4'25 and Q1'26 both $0, despite $820 million of remaining authorization and $650 million of cash), while the founder sold tens of millions of dollars of shares near the late-2025 highs through a 10b5-1 plan; ③ President Jesse Geiger, an 18.5-year veteran, retired on 2026-05-31, and CEO Troendle reassumed the president role, further concentrating power.

One sentence: a high-quality compounding machine, but currently the right business at the wrong time and an expensive price. The current price of $454.25 sits in the upper half of the fair-value band (base $380-460), with no margin of safety. Wait for book-to-bill to move back above 1.0x and confirm a cyclical turn, or wait for the price to fall below $380, before acting.

2. Company Profile

Core business: Medpace is a leading global pure-play, full-service outsourcing (FSO) clinical CRO, covering the full Phase I-IV process: trial design, project management, regulatory affairs, clinical monitoring, data management and statistics, pharmacovigilance, NDA submissions, and post-marketing studies. It also owns central laboratories, bioanalytical laboratories, imaging core labs, and a Phase I clinical pharmacology unit. These facilities are concentrated on the same research campus in Cincinnati, plus Leuven in Belgium, Shanghai, and Singapore. This is real vertical integration, not an outsourced patchwork (FY2025 10-K).

Customer mix, the key to understanding Medpace: About 82% of FY2025 revenue came from small biopharma and 13% from mid-sized biopharma (95% combined). The top ten customers contributed about 35.1%, with no single customer at or above 10% (FY2025 10-K). Small and mid-sized biotech companies usually lack full internal trial capabilities and prefer to hand an entire study to one therapeutically aligned provider. This is exactly the customer base Medpace's FSO model serves well. Larger CROs such as IQVIA and ICON are stronger in the FSP, or functional-service, model for large pharma. The cost is that these customers depend on capital markets, have limited cash runways, and face binary trial outcomes, meaning Medpace demand is highly exposed to the biotech funding cycle.

Therapeutic-area mix (FY2025, gross-method revenue share):

Therapeutic area	Share	YoY dollar change
Oncology	29.5%	+14.8%
Metabolic	29.4%	+62.8% (main growth engine)
Other	16.1%	−5.3%
CNS	10.1%	+40.0%
Cardiology	9.5%	+3.9%
AVAI	5.3%	−13.8%

Metabolic nearly doubled ($457.5M to $745.0M) and is now effectively tied with oncology for first place. About 50% of obesity work is GLP-1 related, and management described GLP-1/metabolic as a “relatively safe” area with the lowest cancellation rate (Q1'26 call).

Scale: As of 2026-03-31, Medpace had about 6,300 employees across 46 countries (Q1'26 10-Q).

Management and ownership: Founder Dr. August J. Troendle (age 69) founded Medpace in 1992. Before starting the company, he served as a medical officer in the FDA's metabolic and endocrine drug division and worked on lipid-lowering drug clinical development at Sandoz (Novartis). He is the only non-independent director on the board and owns about 19.6% of the company, including indirect ownership through Medpace Investors, LLC. Directors and executives together own 20.5% (DEF 14A 2026). Single-class common stock, no dual-class voting rights. Troendle's roughly 20% stake carries equal economic and voting rights, not super-voting rights; the company is not currently a NASDAQ “controlled company.” The CFO is Kevin Brady (since 2021). President Jesse Geiger retired on 2026-05-31, with Troendle reassuming the role.

3. Longitudinal Analysis (History and Share-Price Record)

1992: Troendle founded Medpace in Cincinnati, initially focused on cardiovascular and metabolic work. The company has grown almost entirely through organic growth, with no major acquisitions (Cinven).
Two rounds of PE control: CCMP Capital acquired a majority stake in 2011 for about $485M. Cinven took over in 2014-02 for $915M (about 80% ownership), while Troendle retained a meaningful minority stake and remained CEO (Fierce Biotech).
2016-08 IPO: The deal priced on August 10 at $23.00/share (top of the range), and MEDP began trading on NASDAQ on August 11. Including the overallotment, the company sold 8.05 million shares and raised net proceeds of about $173.6M. All shares were primary and proceeds were used to repay debt, meaning Cinven did not cash out at the IPO (SEC 8-K). Cinven subsequently exited through several secondary offerings plus the company's first buyback (2017-11, 2M shares at $30.16), and fully exited by 2018-08-27 at about 3.5x its money (PE Hub).
Compounding path: Total revenue (including reimbursed costs, on a consistent basis) grew from $421.6M in FY2016 to $2,530.2M in FY2025, a nine-year CAGR of about 22.0% (6.0x). On the net service revenue basis excluding reimbursed costs, $370.6M to $1,492.7M, growth was about 16.7%, again showing that reported growth is amplified by reimbursed costs. Diluted EPS rose from a clean FY2017 base of $0.98 to $15.28 in FY2025, an eight-year CAGR of about 41%. EPS growth has consistently outpaced net-income growth, with the gap almost entirely explained by buybacks reducing the share count.
Aggressive buybacks, no dividends, no stock splits: Since the IPO, the share count has fallen from a peak of about 40-41M to the current 28.56M, down about −30%. In 2025, the company repurchased 2,961,924 shares for $912.9M, at an average price of about $308, and still had $821.7M of authorization remaining at year-end (FY2025 8-K). The high nominal share price of $454 reflects natural compounding, with no split.
Share-price path: IPO at $23 to an intraday high of $628.92 on 2026-01-16 / closing high of $620.59 on 2026-01-21 (about 27x, CAGR around 42%) to the current $454.25 (−27.8% from the high). The 52-week low of $293.20 was around mid-2025. A deeper intraday low around ~$250 occurred during the April 2025 tariff/funding panic but is now outside the rolling 52-week window. The drawdown occurred after two earnings-related selloffs (see Section 8), driven by weakening order leading indicators rather than current-period underperformance (macrotrends).

4. Financial Review

Periodic income statement (USD millions, except per-share data; fiscal year ended 12-31; source: primary SEC 8-K / 10-Q / 10-K filings)

Metric	FY2023	FY2024	FY2025	TTM→Q1'26	Q1 2026
Revenue (net, including reimbursed costs)	1,885.8	2,109.1	2,530.2	2,678.3	706.6
Revenue YoY	+29.2%	+11.8%	+20.0%	—	+26.5%
EBITDA (company basis)	362.5	480.2	557.7	588.5	149.4
EBITDA margin	19.2%	22.8%	22.0%	22.0%	21.1%
Operating profit (EBIT)	336.8	446.9	534.9	562.9	141.5
Operating margin	17.9%	21.2%	21.1%	21.0%	20.0%
Net income	282.8	404.4	451.1	460.4	123.9
Diluted EPS	8.88	12.63	15.28	~15.89	4.28
Net new awards	2,356.7	2,230.0	2,646.8	2,765.2	618.4
Net book-to-bill	—	1.06x	1.05x	~1.03x	0.88x
Ending backlog	2,813.0	2,902.2	3,027.2	2,929.2	2,929.2

Earnings quality is very high, but headline growth needs a haircut:

Balance sheet is exceptionally clean: As of 2026-03-31, cash was $652.7M, interest-bearing debt was $0, and net cash was $652.7M. The 10-Q states that “we had no indebtedness.” Book equity has declined because large buybacks reduce equity, not because operations have deteriorated (Q1'26 10-Q).
Excellent cash conversion: FY2025 operating cash flow was $713.2M, and free cash flow was $681.9M (FCF margin 27.0%), with capex only about 1% of revenue. OCF/net income was 1.58x, driven by negative working capital (about $850 million of customer advances acting as interest-free float) plus a large FY25 non-cash deferred tax item. TTM FCF was about $711M, implying an FCF yield of about 5.5%.
Extremely high ROIC: With zero debt, net cash, negative working capital, and almost no need for net invested capital, ROIC is about 47% even including the $660 million of goodwill created by the 2014 LBO, and above 150% excluding goodwill. This is Medpace's true differentiation, capital efficiency, rather than absolute margin level (see Section 7).
⚠️ The main accounting trap: reimbursed costs amplify reported growth. Zero-margin reimbursed out-of-pocket costs, such as site/investigator payments and travel, rose from 38.3% of FY2023 revenue to 41.0% in FY2025 and 44.2% in Q1'26. In Q1'26, reimbursed costs rose +54.1%, while underlying direct service costs rose only +11.5%. True service growth is far below the +26.5% headline figure. Valuation and peer comparisons must use a consistent basis. FY2025 pure service revenue excluding reimbursed costs was about $1,492.7M.
One-off tax and interest effects: FY2025 tax included an $80.8M non-cash deferred tax item related to the OBBBA Act effective 2025-07-04. Cash taxes were far below book taxes, one of the main reasons OCF was much greater than net income. Q1'25 had an effective tax rate of only 3.0% due to excess tax benefits from equity compensation, lifting the prior-year base and making Q1'26 net-income growth (+8.1%) much weaker than pretax income growth (+24.9%) and EPS growth (+16.6%).

FY2026 company guidance: Revenue of $2.755-2.855B (+8.9% to +12.8%, a clear slowdown from 2025), net income of $487-511M, EBITDA of $605-635M, and diluted EPS of $16.68-17.50 (assuming about 29.2M diluted shares).

5. Moat

Independent third-party rating: Morningstar assigns a “Narrow Moat”, citing intangible assets and high customer switching costs, with advantages sustainable for about 10 years, short of the 20+ years required for a wide moat (Morningstar). This report agrees with “narrow, at most moderately narrow.”

The real sources of the moat:

✅ Trial-level switching costs: Once a late-stage multinational trial begins, switching CROs midstream can damage data integrity, regulatory continuity, and site relationships. This is the core source of stickiness.
✅ Integrated full service + high scientific content: Owned laboratories, imaging, and Phase I units are concentrated in one campus, while a Medical Directors Committee made up of KOLs acts as a gatekeeper for project selection. Scientific rigor is embedded in the process, creating trust with “one-shot” small biotech clients. Medpace is the only global-scale CRO focused on pure FSO.
✅ Capital efficiency rather than pricing power: Medpace's real difference is ROIC of about 47%+, zero debt, negative working capital, and clean GAAP numbers with almost no add-backs. It is not a uniquely high-margin business in a class of its own.

Correcting a popular but wrong argument: The common claim that “Medpace margins crush peers” is apples to oranges, usually comparing Medpace EBITDA margin with IQVIA operating margin. On a comparable adjusted EBITDA basis, IQVIA (23.2%) is actually slightly higher than Medpace (22.0%) (IQVIA FY2025). Medpace's high margin partly reflects customer mix, complex late-stage trials for less price-sensitive small biotech clients, FSO reporting, no acquisition amortization, and an asset-light model. Pricing power is only one part of it.

Why the moat is narrower than bulls claim, the key counterpoint: Medpace's moat is deeply tied to a funding-cycle-fragile customer base, roughly 80% small or single-asset biotech. “Sticky backlog + switching costs” protects wallet share among surviving sponsors, but offers no protection when sponsors run out of money or cut pipelines and directly cancel projects. Backlog can be terminated early by customers and is not contractually certain revenue. This is the root of the 2024-2026 cancellation wave, the slide in book-to-bill to 0.88x, and the securities class action. In other words, what is often packaged as a “niche moat” is substantially exposure to a cyclical, concentrated customer group.

Other durability risks: Key-person dependence, because Troendle's project-selection discipline is highly personal and succession remains unclear, especially after he reassumed the president role; talent retention, because CROs are fundamentally people businesses; scale disadvantages versus IQVIA/ICON, which have more data, RWD, AI platforms, and large-pharma MSA leverage. The sell-side mainstream view, including Jefferies, sees AI disruption to clinical execution as limited, because regulatory, site, patient, and safety processes are hard to automate.

Quantitative positioning: The global CRO market is about $71B (2024), with the small/mid biotech segment around $28-29B. Medpace has about 5-7% share of that segment, consistent across several secondary sources and likely derived from company investor materials, used here as a reference.

6. Industry Demand and the Biotech Funding Cycle

Core tension, the key point of this section: End-market financing clearly improved in 2025H2-2026, but Medpace's own order leading indicators weakened over the same period. This divergence is the central question for the next 12-18 months.

End-market funding is recovering, though the recovery only became clear in 2025H2 and quality matters more than quantity:

XBI (biotech ETF, a funding-sentiment thermometer): Closed at $128.67 on 2026-06-05, with TTM total return of +56.6%, after a strong rebound from the 2025-04 bottom (stockanalysis XBI).
VC: Global biotech VC funding was about $29.7B in 2024 and about $38B in 2025 (+28%). But the year was highly uneven: Q2'25 fell to the weakest level in nearly three years, then Q3'25 rebounded sharply by +70.9% sequentially. H1 was weak, H2 was strong.
IPO/follow-on windows reopened: 2025 follow-on issuance was $56B, exceeding IPO volume. The 2026 IPO window is wide open, with analysts expecting 30-35 biotech IPOs for the year. Pharma M&A has exceeded $106B through early June 2026, and at the current pace could top $250B for the year, the strongest since 2019.
Transmission lag: A funding recovery usually takes 12-15 months (2-4 quarters) to feed into CRO bookings. This is the basis for the bull case, including Jefferies' upgrade of Medpace, that “2026H2-2027 orders accelerate.”

Structural tailwinds: GLP-1/obesity/metabolic trial peak, with 2025 the peak year for GLP-1 activity; continued strength in oncology; rising trial complexity, which increases CRO value per trial; outsourcing penetration still has room to rise, at about 45-50% overall; and small/emerging biopharma contributing more than 50% of the development pipeline.

Structural headwinds:

Cash-runway pressure: EY data show about 39% of listed biotech companies have less than 1 year of cash runway, up from 31% over four years, forcing M&A, layoffs, and pipeline cuts, which map directly to Medpace cancellations.
IRA drug pricing law: About 78% of companies expect to cancel early-stage pipeline projects. Since the IRA was drafted, VC funding for small-molecule R&D has fallen by about 70%, with capital shifting toward biologics. But over a six-quarter aggregate period, total R&D/investment/M&A actually increased, indicating targeted contraction rather than aggregate collapse.
NIH/FDA cuts + tariffs: The proposed 2026 NIH budget reduction is about 40%, FDA layoffs are slowing approvals, and Section 232 pharmaceutical tariffs, with most rates effective from 2026-07-31, mainly hit academic trials and sentiment/regulatory timing. The direct revenue impact on Medpace's commercial customer base is limited, but uncertainty at the RFP stage increases.
Large-pharma R&D growth slowdown: R&D at 13 major pharma companies rose +9.7% in 2024 but is expected to grow only +2.2% in 2025. Medpace skews small/mid-sized, so the direct drag is relatively smaller, but sector sentiment is correlated.

Net reading: End-market industry funding is indeed recovering, but as of 2026Q1 it had not yet flowed through to Medpace's orders/backlog, which instead weakened. The bull-bear debate is whether this is “lagged noise near the cycle bottom that will reverse with funding recovery,” or a “structural share/cancellation issue in the customer base or therapeutic mix.” Whether book-to-bill returns above 1.0x over the next one or two quarters is the decisive verification point.

7. Horizontal Analysis (Peer Comparison)

The public CRO comparable set has narrowed substantially after Syneos went private in 2023, Parexel remained private, and PPD was folded into Thermo Fisher. The remaining set is MEDP / IQV / ICLR, plus early-stage exposure through CRL and the distressed small-cap FTRE.

Comparable table (market data as of 2026-06-05, source: stockanalysis.com; operating data from each company's latest primary filings)

Metric	MEDP	IQV (IQVIA)	ICLR (ICON)	CRL (Charles River)	FTRE (Fortrea)
Market cap	$12.97B	$30.62B	$11.44B	$8.73B	$1.52B
TTM revenue	$2.68B	$16.63B	$8.25B	$4.03B	$2.71B
Latest revenue growth	+26.5%	+4-5%	~flat (−0.4%)	−1.6% (organic)	Declining
Forward PE	26.3x	14.0x	14.2x	15.5x	19.4x
EV/EBITDA	21.1x	14.9x	10.3x	13.1x	35.7x*
Balance sheet	Net cash	Net debt $14.0B	Net debt $2.9B	Net debt $2.9B	Net debt $0.97B

FTRE's EV/EBITDA is distorted by depressed reported EBITDA; on adjusted EBITDA, it is about 13x. ICON's trailing PE of 51.5x is distorted by 2025 impairments, including $365M of goodwill; on adjusted EPS, it is about 11-12x.

Peer status: IQVIA's growth has slowed to the low to mid-single digits, the stock has de-rated, and leverage is high. ICON is struggling, with FY25 revenue flat, multiple guidance cuts, and a governance overhang from 2025 revenue restatement and internal-control review. CRL, which is more preclinical/early-stage and not a pure clinical CRO, had organic growth of −1.6% and is in strategic rebalancing. Fortrea is the most distressed, with high debt after the spin-off, an FY25 net loss of $986 million, including a $798 million goodwill impairment.

Medpace's premium and judgment: MEDP's trailing PE is about a +26% premium to IQVIA, the only large peer with clean positive earnings. Its forward PE is about a +65-85% premium to the peer average of 15.8x.

Why the premium makes sense, the bull case: Organic growth crushes peers (+26% versus generally flat to low-single-digit growth), and all of it is organic with no acquisition assembly; net cash versus generally high peer leverage, with no acquisition-debt drag; clean, high-quality earnings versus peers relying on add-backs and impairment charges; and deep founder alignment.
Why the premium is fragile, the bear case: A 26x forward multiple prices in “sustained high growth,” while Q1'26 book-to-bill has already fallen to 0.88x and cancellations are rising. Leading indicators point toward convergence with the +10% guidance range. Sell-side consensus is already Hold, with an average target of about $443, around −2.5% versus the current price, meaning the Street views the stock as fair to slightly expensive.
Partially de-rated already: The stock is down 28% from its high, so part of the slowdown risk is already priced in. But the absolute valuation premium remains.

Sell-side coverage (dated): Consensus rating is Hold. As of the 2026-04-24 stockanalysis snapshot, 13 analysts had an average target of $442.83, median $456, and range of $329-$495. The February bull-target group, Jefferies at $560, Baird at $564, and Mizuho at $582, all betting on a funding inflection, pulled back after Q1'26 book-to-bill came in at 0.88x.

8. Current Fundamentals (Why the Stock Is Down −28% From the High)

Key point: this is an order/forward-demand story, not a current-performance story. Revenue and EPS beat expectations for two quarters, yet the stock was still marked down.

First drop, Q4'25 earnings (2026-02-09, −15.9% in one day, $530.35 to $446.05): Revenue was $708.5M (+32.0%), and EPS was $4.67, above the $4.18 consensus, so both beat expectations. But Q4 net book-to-bill was only 1.04x, below management's prior 1.15x guide, and the CEO acknowledged that cancellations reached a more-than-one-year high. At the same time, FY2026 revenue-growth guidance was set at +8.9%-12.8%, a sharp deceleration from +20% in 2025.

Second drop, Q1'26 earnings (2026-04-22/23, about −21% in one day, the most important event):

Revenue was $706.6M (+26.5%, above consensus of about $696M), diluted EPS was $4.28 (about $0.54 above consensus of roughly $3.74), and adjusted EBITDA was $149.4M, also above expectations. Again, both revenue and EPS beat. FY2026 guidance was maintained unchanged.
The fatal metric: net book-to-bill fell to 0.88x, the first time below 1.0. Net new awards were $618.4M, up +23.7% YoY but down sequentially from $736.6M. Gross awards were “at the low end,” cancellations again reached a more-than-one-year high and were concentrated in oncology and cardiovascular. Backlog was $2,929.2M, down −3.2% from $3,027.2M at Dec'25, with only about $1.94B converting to revenue over the next 12 months. Net margin compressed to 17.5%.
Simultaneous shock: The company disclosed that President Jesse Geiger, an 18.5-year veteran, would retire on 2026-05-31, with CEO Troendle reassuming the president role.
Management commentary on the Q1 call: biotech funding had been “stable” over the past eight or nine months, but RFP volume declined. Cancellations were mainly due to “product performance/pipeline reprioritization,” not acute funding shortages. Management acknowledged that “future six-month sequential growth is a real issue” and that backlog coverage had declined for six consecutive quarters, with “things to worry about.” It downplayed AI impact (Q1'26 call).

Summary: Two consecutive quarters of revenue/EPS beats were overwhelmed by deteriorating leading indicators: book-to-bill from 1.04x to 0.88x, record cancellations, softer RFPs, slower guidance, margin pressure, and executive departure. The market is pricing future deceleration.

9. Valuation

Medpace has clean earnings and strong cash flow, so PE / EV-EBITDA / FCF yield are the valuation anchors, rather than revenue multiples.

Current price coordinates: $454.25 = 28.6x trailing PE / about 26.6x forward PE (FY26 EPS midpoint $17.09) / about 21x EV-EBITDA (EV ≈ $12.3B) / FCF yield of about 5.5%.

Three scenarios (using FY2026 EPS midpoint of $17.09 and forward multiples as the main axis, with cycle and peer references):

Scenario	Assumptions	Valuation range	Forward PE
Bear	book-to-bill remains <1.0, growth stalls to high single digits, multiple compresses; litigation settlement and/or second cyclical downturn	$290 – $360	~17-21x
Base	FY26 guidance maintained (+9~13%), multiple holds, cycle slowly recovers	$380 – $460	~22-27x
Bull	book-to-bill returns >1.0, growth returns to mid-teens, rerating toward prior highs	$520 – $600	~30-35x

The current price of $454.25 sits in the upper half of the base band ($380-460), consistent with sell-side consensus median of $456 and average of $443. It is fair to slightly expensive, with no margin of safety.
Ideal buy ≤ $380 (the lower end of the base band, about 22x forward PE, roughly −16% below the current price). This is the margin of safety required for “decelerating cyclical earnings + litigation overhang.” Given business quality, investors do not need to wait for the bear-case band to act, but they should not chase a full price while leading indicators are moving down.

Why the rating is not higher: The base-case midpoint of about $420 is only in line with or slightly below the current price, supporting Hold rather than Buy. With leading indicators falling, litigation pending, and an inflection still unproven, “Watch, wait for confirmation or price” is more honest than Hold.

10. Risks

Demand-cycle risk, the largest: About 80% of revenue comes from funding-sensitive small biotech. If the XBI/IPO window cools again, Medpace bookings are first in line to suffer. Book-to-bill of 0.88x is direct evidence.
Further deterioration in leading indicators: If Q2'26 book-to-bill remains below 1.0 or guidance is cut, backlog erosion will be confirmed and another de-rating may follow.
Valuation risk: 26x forward earnings for an earnings stream slowing toward +10% and exposed to the cycle. PEG is deteriorating, and downside elasticity is large.
Securities class action: Durbin v. Medpace (1:26-cv-00346, S.D. Ohio, §§10(b)/20(a), class period 2025-04-22 to 2026-02-09), alleging management dressed up worsening cancellation rates/book-to-bill as “very well behaved.” The lead-plaintiff deadline was 2026-06-08, and the amended complaint/motion-to-dismiss cycle will create 12-18 months of headline and settlement risk.
Key person + governance: Troendle combines Chairman + CEO + newly reassumed President, with unclear succession. Related-party transaction concerns are substantial in tone: the company leases multiple office buildings from Troendle family entities; the CEO-owned on-campus Summit Hotel receives about $0.3M of company travel spending per year; one EVP cohabits with the CEO; and several biotech companies where Troendle serves as a director, including LIB Therapeutics, CinRx, CinCor, and Coherus, are or were Medpace customers. This “founder-funded biotech hires Medpace” structure creates a structural conflict of interest. The dollar amounts are not large, but it is a qualitative observation item.
Capital-allocation signal: After the share price fell below $600, buybacks went to zero (Q4'25 and Q1'26 both $0, despite $820 million of remaining authorization and $650 million of cash), while the founder sold tens of millions of dollars near late-2025 highs through a 10b5-1 plan. The best-informed person was reducing buy-side exposure. Exact sale totals vary across sources, so this report uses only the directional signal.
Margin pressure: Rising direct costs have reduced Q1'26 net margin to 17.5%; the rising reimbursed-cost share further dilutes reported margins.
Policy/macro: IRA, NIH/FDA cuts, and Section 232 tariffs indirectly restrain customer R&D budgets.

Pre-mortem (if the stock is down −30% to −45% one year from now, the most likely reason): Q2/Q3'26 book-to-bill stays below 1.0, FY2027 guidance points to low-single-digit or even zero growth, and the market reprices the company from a growth stock to a mature cyclical stock, compressing the forward multiple from 26x to 15-18x, with material progress in the class action adding pressure. That is the classic double hit of “high-quality business + full-price valuation” in a cyclical downturn.

11. Catalyst Tracking

Negative/watch items:

Q2'26 earnings (around late July 2026), the core swing event: Another book-to-bill print below 1.0 or a guidance cut would confirm backlog erosion. The cancellation trend is the key tell.
Q3'26 (around late October) + preliminary FY2027 guidance (around February 2027): FY27 guidance will embed weak 2026 bookings, with high risk of softness or deceleration.
Litigation progress: Lead-plaintiff selection (deadline 2026-06-08) → consolidated complaint → motion-to-dismiss cycle.
Leadership transition execution: Selection of a permanent president, Troendle's interim concentration of authority, and whether further executives depart.

Positive/upside catalysts:

Book-to-bill returns above >1.0x: In a weak sentiment environment, even a single quarter above 1.0 could be a strong positive catalyst. Management says the opportunities are “high quality.”
Buybacks resume: $820 million of unused authorization + $650 million of cash + strong FCF. If the company resumes repurchases around ~$454, well above the 2025 comparison base of about ~$308 but far below the $600s, it would both accrete EPS and signal confidence.
Biotech funding/XBI recovery + rate cuts revive RFP activity; GLP-1/obesity demand remains resilient.
Guidance delivery: Maintaining FY26 EPS of $16.68-17.50, after valuation has already reset (target about ~$443 versus current price about ~$454), would de-risk the story.

12. Zen Horizon Intersection (Integrated Judgment)

From the longitudinal perspective, Medpace is a proven high-quality compounding machine: 32 years of organic growth, zero debt, net cash, ROIC of about 47%+, revenue CAGR of about 22% since IPO, share count down 30% through buybacks, and deep founder alignment. From the horizontal perspective, its organic growth outpaces all listed peers, and its earnings quality and balance sheet are unmatched. The premium has a rational core.

But the two axes intersect in 2026 at an uncomfortable conclusion. The machine's fuel, small and mid-sized biotech funding, is in a divergence phase: end-market funding is improving, but it has not yet flowed through to Medpace's own orders. Meanwhile, leading indicators, book-to-bill from 1.20 to 1.04 to 0.88, are flashing yellow for several quarters in a row. At the same time, the market still gives the company a 26x forward growth-stock valuation. There is a gap between the quality of the business, which is worth owning, and the current odds, which are not attractive enough to chase. Add the litigation overhang and capital-allocation signals of “buybacks paused + founder selling,” and the case supports Watch rather than Buy or Hold.

Conclusion restated: Watch. Ideal buy ≤ $380. This is a high-quality company that belongs on a watchlist while investors wait for better odds. Two conditions could trigger a buy: ① book-to-bill rises back above 1.0x with cancellation rates falling, confirming a cyclical turn; or ② the price falls below $380, creating a margin of safety. Until then, full valuation + falling leading indicators + litigation uncertainty mean the current price is not an attractive entry point.

Research Uncertainties

Underlying service growth is not separately disclosed: The company does not separately disclose service revenue excluding reimbursed costs. This report's “about +11.5%” estimate is an approximate proxy based on Q1'26 direct service cost growth, not the company's own revenue metric.
Founder sale totals vary by source: Different secondary sources use different share-count and dollar-value bases for Troendle's late-2025 sales. This report uses only the directional signal: near the highs, through 10b5-1, and in the tens-of-millions range, without relying on a single precise total.
52-week low date is not pinned to the exact day: It was around mid-2025. The deeper intraday low near ~$250 in 2025-04 has moved outside the rolling window.
Related-party transaction dollar amounts: Except for the on-campus hotel at about $0.3M per year, the specific amounts for related-party leases and revenue from Troendle-affiliated biotech companies require 10-K Item 13 detail. This report verifies that the relationships exist but does not quantify each item.
Valuation scenarios are framework ranges and are sensitive to FY2027 growth and multiple assumptions. The timing of the book-to-bill inflection is the largest variable.
Absolute CRO market-size estimates vary by up to 2x across third-party reports ($45B-$93B). This report uses only the more reliable CAGR direction (7-10%) and segment-share direction.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.

Mentioned Tickers

IQV ICLR CRL FTRE TMO

Baillie Framework · Ten Questions for Growth Investing

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

How large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?6/10

Conclusion: Medpace has a sufficiently high market ceiling, but it is continuing to penetrate and take share within the existing clinical CRO outsourcing market, rather than creating a new market. Using the report's common anchor, the global CRO market is about $71B, and the small/mid biotech segment is about $28-29B; external estimates broadly support this scale as well, such as a 2024 global CRO services market of $68.4B, with 2034 expected at $142.7B and a CAGR of 7.6%, and another estimate of 2024 at $66.39B and 2030 at $122.13B, with clinical outsourcing penetration of about 45%-50%. This means the pie itself is still growing, but it is not a blue-ocean new category.

Medpace's real addressable opportunity is not the entire CRO market, but "full-service Phase I-IV clinical development for small and mid-sized biotech." The company had FY2025 revenue of $2.5302B, of which 82% came from small biopharmaceutical and 13% from mid-sized biopharmaceutical, totaling 95%. But the accounting trap flagged in the report matters here: FY2025 reported revenue included $1.037B of reimbursed out-of-pocket costs; excluding those pass-through costs, pure service revenue was about $1.493B. On that basis, against the relevant $28-29B segment, Medpace's share is about 5-7%, leaving substantial theoretical room.

So under Baillie Q1, the ceiling is not the main weakness. If the small/mid biotech CRO segment nearly doubles over the next decade as the industry grows and outsourcing penetration rises, Medpace can grow simply by holding share; if it can also lift share from 5-7% to the low double digits, revenue above $5B is not far-fetched. Add FY2025 FCF margin of 27.0%, ROIC of about 47%+, zero debt, and long-term share repurchases that shrink the share count, and the market space is enough to support long-term compounding.

But it should not be framed as "creating a new market." GLP-1/obesity, metabolic, oncology, and complex global trials are indeed lifting CRO workloads. Medpace's metabolic revenue reached $745.0M in FY2025, accounting for 29.4%, and management said about half of obesity work is GLP-1 related, with lower cancellation rates. This is more like a high-growth demand wave inside the existing CRO market, not a new industry. The real constraints are not TAM, but the biotech funding cycle, customer cancellation rates, the terminability of backlog, and competition from large CROs such as IQVIA/ICON. The current Q1'26 net book-to-bill has fallen to 0.88x, which means "high ceiling" and "weak near-term orders" must both be true at the same time.

Jun 6, 2026
Can its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?4/10

Conclusion: a five-year revenue doubling is possible, but it cannot be treated as the base case today. Starting from FY2025 revenue of $2.5302B, doubling in five years implies about $5.06B of revenue and requires roughly 14.9% annualized growth; but the company's FY2026 guidance is only $2.755-2.855B, or +8.9%-12.8%, so the first year is already below the pace required for doubling. If FY2026 lands within guidance, FY2027-2030 would still need about 15.4%-16.4% compound growth for four consecutive years, making the bar meaningfully higher.

The real obstacle is not historical capability, but the current order signal. Medpace has indeed proven it can grow organically at high speed: FY2016 to FY2025 total revenue rose from $421.6M to $2.5302B, about a 22% CAGR; but the report also notes that net service revenue excluding pass-through costs had a CAGR of about 16.7%, closer to the true business momentum. Now the leading indicators are weakening: net book-to-bill moved from 1.20x(Q3'25) to 1.04x(Q4'25), then to 0.88x(Q1'26). Q1'26 backlog of $2.9292B fell 3.2% sequentially from $3.0272B at 2025 year-end, and management also acknowledged lower RFP volume and that sequential growth over the next six months is an issue (Q1'26 call). This does not look like a company already on a five-year doubling track; it looks more like a high-quality cyclical growth stock that needs confirmation of an order inflection first.

If it ultimately does double, the main driver will be volume, not price, and not an entirely new business. Volume would come from clinical trial starts after small and mid-sized biotech funding recovers, higher outsourcing penetration, trial complexity, and scaling in therapeutic areas such as metabolic/GLP-1. About 82% of Medpace's FY2025 revenue came from small biopharma and 13% from mid-sized biopharma, so the business model is naturally tied to the funding and pipeline progress of these customers (FY2025 10-K). Price should contribute only modestly; a CRO is not software with strong pricing power. "New business" should not be overstated either: GLP-1/metabolic is more a therapeutic-area mix shift within the core CRO business than a second curve.

Special caution is also needed on the quality of headline revenue: Medpace recognizes revenue on a gross basis including pass-through costs. In Q1'26, pass-through costs had already reached 44.2% of revenue, and pass-through costs were up +54.1% year over year, far above the underlying direct service cost increase of +11.5% (Q1'26 10-Q). So even if reported revenue appears close to doubling, the question is whether high-quality service revenue and cash flow are growing, or whether zero-margin pass-throughs are inflating revenue. The current answer is: a five-year doubling is a bull case, and the key verification point is whether book-to-bill can return to and stay above 1.0x over the next few quarters; before that, Q2 cannot receive a strong conclusion.

Jun 6, 2026
Five years from now, what will take over as the next growth engine? Does this "second curve" exist today?4/10

Conclusion: there is a "candidate second curve," but it cannot yet be called a validated strong second curve. The most plausible successor is metabolic / obesity / GLP-1 related cardiometabolic clinical trial demand, not AI, a data platform, M&A, or large pharma outsourcing. It already exists today: FY2025 metabolic revenue was about $745.0M, accounting for 29.4% of revenue and up +62.8% year over year, almost matching oncology's 29.5%; Q1'26 metabolic revenue was $237.6M and remained one of the main growth drivers. These therapeutic-area data points can be cross-checked in the company's FY2025 10-K and Q1'26 10-Q.

But the nature of this curve needs to be clear: it is more a "therapeutic-area migration inside the core CRO engine" than a new business. Medpace remains a full-service Phase I-IV CRO, with about 95% of revenue from small/mid biopharma; the company has not disclosed a standalone data/RWD/AI platform, platform-like expansion in diagnostics labs, or a new growth flywheel based on large-pharma MSAs. Management also stated clearly on the Q1'26 call that AI would have limited net benefits for at least the next year or two because required investment would offset efficiency gains; large pharma is also not the company's strategic focus, and it continues to prioritize the full-service model for small and mid-sized biotech (Q1'26 call).

So if the question is what takes over around 2031, the most reasonable answer is broad cardiometabolic, especially long-duration, large-sample, complex clinical programs driven by obesity, diabetes, GLP-1, and spillover indications. Management said about 50% of obesity work is GLP-1 related, and metabolic has historically had lower cancellation rates, showing this is not castles in the air (Q1'26 call). The problem is that this curve is already large today. In FY2025, metabolic was almost tied with oncology for first place; the more it has already entered the main revenue pool, the harder it is to view it as a new successor five years from now.

The bigger deduction is that the order side has not validated it. Q1'26 revenue was $706.6M, net new awards were $618.4M, net book-to-bill was only 0.88x, and backlog was $2.9292B. The company's own Q1'26 earnings release lays out this leading indicator; the call also mentioned sequential and year-over-year RFP declines, elevated cancellations, and the real issue of sequential growth over the next six months. A true second curve should first show up in bookings, backlog, and improved cancellation rates, not just an attractive current revenue mix.

My judgment: Q3 is not so weak that there is no second curve, but it is also far from a strength that deserves confident Baillie-style extra credit. The second curve that exists today is "early-to-mid-stage scaling of metabolic/GLP-1 related clinical demand," not "a second flywheel created by an upgrade in Medpace's business model." What matters next is not the story, but whether book-to-bill can return to >1.0x for several consecutive quarters, and whether metabolic orders keep growing without being swallowed by cancellations; otherwise, the so-called second curve is essentially the first curve waiting for the biotech funding cycle to repair.

Jun 6, 2026
What is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

Conclusion: Medpace's core competitive advantage is not "the largest scale" or "crushing margins," but a full-service, integrated, science-driven CRO model for small and mid-sized biotech + trial-level switching costs. I would characterize this moat as a "narrow moat, high quality but not wide enough." Over the next three to five years, it is more likely to hold steady to narrow slightly unless book-to-bill stabilizes back above 1.0x, proving that a funding-cycle recovery is again flowing through to bookings.

The first layer of advantage is customer fit. The report notes that in FY2025, about 82% of Medpace revenue came from small biopharma and 13% from mid-sized, or about 95% combined; these customers usually lack complete clinical development teams and are more inclined to hand Phase I-IV, regulatory, data, pharmacovigilance, laboratory, imaging, and other processes to a single CRO. The company itself also emphasizes that its differentiation comes from full-service Phase I-IV clinical development services and therapeutic-area expertise. Once a late-stage clinical trial has started, switching CROs midstream damages data continuity, site relationships, and the regulatory timeline, so customer switching costs are real.

The second layer of advantage is execution discipline and capital efficiency. The hard numbers in the report are strong: FY2025 revenue of $2.5302B, EBITDA margin of 22.0%, operating margin of 21.1%, and FCF margin of 27.0%; as of 2026-03-31, cash was $652.7M and interest-bearing debt was $0; ROIC including goodwill was about 47%+. This means Medpace's moat is expressed more through a compounding structure of "high-quality execution + asset-light operations + negative working capital + limited M&A amortization" than simply through higher pricing. Morningstar gives it a narrow moat, which is closer to reality than a "wide moat" label.

The issue is that this moat cannot stop customers from running out of money or cutting pipelines. Medpace's customer base is highly sensitive to the funding cycle, with 82% of FY2025 revenue from small biopharma, and the company's 10-K explicitly says most clinical service contracts can be terminated by customers without cause on 30 days' notice. This explains why the report treats Q1'26 net book-to-bill of 0.88x, backlog declining sequentially from $3.0272B to $2.9292B, and cancellations reaching the highest level in more than a year as serious: switching costs can protect "projects that remain alive," but cannot protect against sponsors losing funding, project failure, or pipeline reprioritization.

So over the next three to five years, I do not think the moat will widen significantly. On the positive side, metabolic/GLP-1 and complex clinical trials will continue to reinforce its science-led full-service positioning, and the report also notes that FY2025 metabolic revenue accounted for 29.4% and grew +62.8% year over year. But the negatives are harder: RFPs are down sequentially and year over year, book-to-bill has fallen below 1.0 for the first time, management admits that "sequential growth over the next six months is a real issue," and relative to IQVIA/ICON, Medpace lacks large-pharma MSAs, RWD/data platforms, and larger-scale global data assets. My judgment is: the business remains excellent, and the moat is still there; but it is a narrow and deep specialist moat, not a structural monopoly moat that widens through cycles.

Jun 6, 2026
If its core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?4/10

Conclusion: neutral to somewhat weak. Medpace has the adaptability to reallocate resources within clinical CRO, but there is still no strong evidence of an ability to switch tracks and reinvent itself after its core business is disrupted. It looks more like a founder-led, highly disciplined professional-services machine than a compound organization that can keep incubating second business platforms.

The positive evidence is that it can indeed shift therapeutic focus as demand migrates. Founded in 1992, the company has long pursued organic expansion around full-service Phase I-IV CRO; FY2025 revenue was $2.5302B, up +20.0% year over year, and the metabolic business had risen to 29.4%, almost matching oncology's 29.5%, with metabolic revenue up +62.8% year over year; management also said about 50% of obesity work was GLP-1 related, and GLP-1/metabolic cancellations were relatively low. This shows Medpace can reallocate medical execution, site management, laboratory/imaging/Phase I capabilities to hot indications instead of being frozen inside one type of trial. The balance sheet also gives it room to experiment: as of 2026-03-31, cash was $652.7M, there was no interest-bearing debt, and the Q1 10-Q explicitly disclosed no debt.

But this is not strong reinvention in the Baillie sense. Medpace's 10-K says it is "solely focused" on science-driven outsourced clinical development services and uses the full-service Phase I-IV model as its core differentiation; the company also manages itself as one operating segment, showing it has no already formed second engine or platform business. In FY2025, about 82% of revenue came from small biopharma and 13% from mid-sized biopharma, totaling 95%; if this customer base faces a funding gap, pipeline reprioritization, or acquisition by large pharma, Medpace's moat has limited protective power. The company also reminds investors in its 10-Q that most customers can terminate contracts without cause on 30 days' notice, and backlog and net awards are not the same as guaranteed revenue; Q1'26 backlog of $2.9292B, down -3.2% sequentially from $3.0272B at 2025 year-end, is an expression of that fragility.

Its attitude toward AI/data-platform disruption is also practical but not aggressive. On the Q1'26 call, Troendle said AI has value, but net benefits over the next year or two would be offset by investment, and customer-side AI applications have not yet truly affected Medpace's service delivery. That is an honest assessment, not blind hype chasing; but from the perspective of a "great growth stock for five to ten years," it also means the company has not yet proven it can turn AI, RWD, or data platforms into a new competitive layer. Compared with companies such as IQVIA/ICON, which have larger data assets and more leverage with large-pharma MSAs, Medpace has a narrower reinvention toolkit.

Its handling of bad news is "candid, but somewhat late and somewhat sparse." On the positive side, the Q1'26 call did not gloss over every problem: management acknowledged cancellations at the highest level in more than a year, sequential and year-over-year RFP declines, gross awards at the low end, and net book-to-bill falling to 0.88x; Troendle also admitted sequential growth over the next six months is a real issue and said cancellations need to fall or gross awards need to improve. Publicly acknowledging bad news like this is a plus.

The deductions are equally clear: communication quality before the bad news reached the market was not high enough. The company had previously given stronger book-to-bill expectations, but 2025Q4 came in at only 1.04x and 2026Q1 fell further to 0.88x; the ongoing Durbin v. Medpace class action centers precisely on securities fraud allegations about whether management downplayed worsening cancellations and book-to-bill. The lawsuit itself has not proven management violated the law, but as an observation point for "bad-news transparency," it is a negative signal. Add that Q4'25/Q1'26 repurchases were $0 despite $821.7M of authorization remaining at the end of Q1, while the founder set up/executed a 10b5-1 selling plan near high prices at the end of 2025, and the capital-allocation signal does not align cleanly with a "long-term undervaluation buy" narrative.

Therefore, Medpace cannot score highly on Q5: it has the adaptability of a professional-services company, founder discipline, and financial cushion, but its reinvention is more "adjusting direction within the same lane" than "building another Medpace after the original lane is disrupted." It ultimately tells the truth when facing bad news, but the cadence and granularity of disclosure are not enough to classify it as a highly transparent, proactive self-correcting management team.

Jun 6, 2026
Does management, especially the founder, have a long-term view and deeply aligned interests with the company? Is it willing to sacrifice current profits for the next five to ten years?7/10

Conclusion: Q6 is relatively strong, but not perfect. Medpace's management alignment is real: August J. Troendle is the 1992 founder, and the 2026 DEF 14A shows he still serves as CEO/Chair, with board tenure dating back to the company's founding; the same proxy shows he owns/beneficially owns 5,653,390 shares, about 19.6%. Using the report's price anchor of $454.25, this is not symbolic ownership; a major portion of his wealth remains tied to the company's long-term value.

There is also hard evidence of a long-term view: the company has not built scale through acquisitions, but has stayed focused on full-service CRO for small and mid-sized biotech; the report gives a FY2016-FY2025 revenue CAGR of about 22%, and the post-IPO share count has fallen from about 40-41M to 28.56M, or about -30%. FY2025 OCF was $713.2M and FCF was $681.9M, and 2026Q1 cash was $652.7M with interest-bearing debt of $0. This shows Troendle's operating style is more "focus, restraint, cash flow, and capital efficiency first" than the typical professional manager's pursuit of quarterly KPI or leveraged expansion.

But the evidence that management is willing to sacrifice current profits for five to ten years out is only moderate. Medpace has long maintained owned laboratory/imaging/Phase I capabilities and a science-driven full-service model, which does place trial quality and customer continuity first; but it is not a model that deliberately suppresses margins to expand long-term TAM. The report instead emphasizes ROIC of about 47%+, EBITDA margin of 22.0%, and capex of only about 1% of revenue. In other words, management has long-term operating discipline, but it is not the kind of founder-led reinvestment model that sacrifices current-year profit for a platform ten years out.

The deductions also need to be stated plainly. First, President Jesse Geiger retired on 2026-05-31, and Troendle reassumed the President role; the official disclosure said Geiger's departure was not due to disagreements over operations/policies, but this still increases key-person dependence. Second, the capital-allocation signal is not clean enough: in FY2025 the company repurchased 2,961,924 shares for $912.9M, but it made no repurchases in Q4'25 or Q1'26 despite $821.7M of authorization still remaining at the end of 2026Q1; meanwhile, the 10-K disclosed that Troendle had set up a Rule 10b5-1 sale arrangement in 2025-11 for up to 150,000 shares. Third, governance has related-party noise, such as 2025 revenue recognized by Medpace of $7.9M from LIB and $45.3M from CinRx, entities connected to insiders including the CEO through board roles/ownership; the CEO-owned The Summit Hotel also had $0.3M of company spending.

So the answer to this question is: founder alignment is very strong, and long-term operating capability and capital discipline are also strong; but succession, related-party transactions, the late-2025 selling arrangement, and securities-litigation risk disclosed in the Q1'26 10-Q mean this is not a flawless founder-governance case. For Baillie LTGG, Q6 is a positive for MEDP and supports the "quality growth stock" foundation; but it is not enough to offset more immediate odds issues such as Q1'26 book-to-bill of 0.88x, growth guidance reduced to +8.9%-12.8%, and the current price of $454.25 sitting in the upper half of the base range.

Jun 6, 2026
If it disappeared tomorrow, how much would customers miss it? Is its growth sustainable, without relying on social harm or regulatory arbitrage?6/10

Conclusion: customers would miss Medpace, but it is not so indispensable that the industry would stall without it. For clinical trials already underway, especially late-stage projects at small and mid-sized biotech, its disappearance would hurt: the report anchors FY2025 revenue at about 82% from small biopharma and 13% from mid-sized, and Medpace is a full-service CRO covering Phase I-IV; these customers often lack complete clinical execution, regulatory, data, laboratory, and pharmacovigilance capabilities. The company also positions itself in its FY2025 10-K as a full-service Phase I-IV clinical development platform, providing regulatory affairs, clinical monitoring, data management, pharmacovigilance, NDA submission, post-approval support, and other services. Switching CROs would damage timelines, site relationships, data continuity, and filing cadence.

But it is not a wide-moat "only gateway." The same FY2025 10-K explicitly lists IQVIA, ICON, PPD/Thermo Fisher, Fortrea, specialized/regional CROs, and in-house pharma R&D as competitors; more importantly, most clinical service contracts can be terminated without cause, typically on about 30 days' notice. The order data in the report also reinforces this point: net book-to-bill moved from 1.20x(Q3'25) to 1.04x(Q4'25) and then to 0.88x(Q1'26); Q1'26 net new awards of $618.4M were below revenue of $706.6M, and backlog also fell from $3.0272B in Dec'25 to $2.9292B. A truly irreplaceable company typically would not see orders cut this quickly when customers reprioritize pipelines, face funding pressure, or tighten budgets.

The growth model itself is socially and regulatorily friendly; it does not rely on harming users or regulatory arbitrage. The core value of a clinical CRO is to execute drug/device trials properly under GCP, IRB, informed-consent, adverse-event reporting, data-integrity, and other requirements; Medpace discloses that its clinical trial services are directly subject to FDA, IRB, GCP, and other regulatory requirements and must protect participant safety and data reliability. In other words, compliance is not an obstacle to its growth, but the reason customers are willing to pay.

The weakness is "economic sustainability," not "social sustainability." MEDP's financial quality is strong: FY2025 revenue of $2.5302B, EBITDA margin of 22.0%, FCF margin of 27.0%, net cash of $652.7M, and ROIC of about 47%+; but its growth fuel still comes from the funding, pipeline outcomes, and outsourcing budgets of small and mid-sized biotech. Although Q1'26 revenue was up +26.5% year over year, net new awards were $618.4M and backlog was $2.9292B, and backlog/award metrics can be affected by cancellations and changes in project scope; management also acknowledged that cancellations were at a more than one-year high and that RFPs were down sequentially and year over year.

So the Q7 judgment is: Medpace is "very useful, painful to switch away from" for customers with active trials, but "substitutable" for the industry; the business model is healthy in social and regulatory terms, but growth is not a self-driving perpetual motion machine. Under Baillie standards, this is an above-average clinical execution asset, not a top-tier indispensable platform.

Jun 6, 2026
What are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate with scale? Where does the money it earns go?6/10

Conclusion: Medpace's unit economics are strong, but the accounting noise needs to be stripped out. FY2025 revenue was $2.5302B and total direct costs were $1.7696B, which gives a direct gross margin of about 30.1% using reported "revenue minus direct costs"; but $1.0375B of this was reimbursed pass-through costs billed to customers at cost. Excluding those, pure service revenue was about $1.4927B and service direct gross margin was about 50.9% (FY2025 10-K). Q1'26 showed the same pattern: revenue of $706.6M, pass-through costs of $312.0M, direct service costs of $198.3M, and service direct gross margin of about 49.8%; but reported direct gross margin fell to about 27.8% because pass-throughs rose to 44.2% of revenue, and pass-through costs were up +54.1% year over year, far faster than direct service costs at +11.5% (Q1'26 10-Q).

Incremental returns are even better. The report gives FY2025 operating cash flow of $713.2M, FCF of $681.9M, FCF margin of 27.0%, and OCF/net income of 1.58x; capex was only about 1% of revenue, and ROIC including goodwill was about 47%+. This shows it does not earn incremental profit through heavy-asset expansion, but by turning additional projects into cash flow through expert teams, processes, customer prepayments, and asset-light facilities.

As scale increases, the structure should improve in normal conditions but deteriorate during cyclical downturns. In normal conditions, more projects spread SG&A and improve personnel and laboratory utilization. From FY2023 to FY2025, operating margin rose from 17.9% to 21.1%, and EBITDA margin stayed around 22%; but 2026Q1 has already shown the other side: pass-through mix rose, net book-to-bill fell to 0.88x, and backlog declined sequentially. If orders are insufficient, CRO labor costs and fixed facilities will weigh on utilization, and scale advantages will temporarily work in reverse.

The money it earns mainly goes to three places: first, talent, facilities, equipment, and technology needed for organic expansion, with FY2025 capex of about $31.4M; second, cash retained on the balance sheet, with $652.7M of cash and zero interest-bearing debt as of 2026-03-31 (Q1'26 10-Q); third, share repurchases, with FY2025 repurchases of 2.9619M shares for $912.9M and $821.7M of authorization still remaining at year-end, though there were no repurchases in Q4'25 or Q1'26 (FY2025 8-K). So Q8 is relatively strong: this is a good business with high cash conversion and high returns on capital; the weakness is not the unit economics themselves, but the current order cycle and paused repurchases, which require renewed proof that the strong unit economics can keep compounding.

Jun 6, 2026
What conditions must hold simultaneously for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?3/10

Conclusion: for MEDP to rise fivefold in ten years from the 2026-06-05 closing price of $454.25, the target would be about $2,271/share, which roughly implies a $65B market cap based on the current share count. This cannot be achieved simply by "a good company compounding gradually"; it requires an order-cycle reversal, revenue returning to mid-teens growth, margins/ROIC not falling, continued low-price repurchases, and a high valuation still being awarded ten years from now, all at the same time.

Working backward from EPS makes it more intuitive: the company's FY2026 guidance is revenue of $2.755-2.855B and EPS of $16.68-17.50, with a midpoint of about $17.09 (company Q1'26 guidance). If the market still assigns about 26.6x PE ten years later, EPS would need to reach about $85, implying a ten-year EPS CAGR of about 17.5%; if the mature multiple is only 20x PE, EPS would need to reach $114, requiring EPS CAGR of about 21%. That likely means revenue has to grow from about $2.8B in 2026 to $10B or more, while maintaining close to the current 20%+ EBITDA margin, strong cash conversion, and continued share-count reduction through repurchases.

Among these conditions, the hardest first gate is orders. The report notes that MEDP's net book-to-bill has moved from 1.20x(Q3'25) to 1.04x(Q4'25), then to 0.88x(Q1'26), and Q1 backlog also fell from $3.027B to $2.929B; although Q1 revenue was still +26.5%, orders and backlog have already weakened first (company Q1'26 results). So the fivefold scenario requires this to be a short-term lag before a biotech funding recovery flows through to CRO bookings, not structural deterioration; over the next few quarters, book-to-bill must climb back above 1.0x and preferably return above 1.1x.

The second gate is growth quality. MEDP cannot merely use pass-through costs to prop up headline revenue; the report specifically warns that Q1'26 pass-through costs were up +54.1% year over year while underlying direct service costs were only up +11.5%, indicating that the apparent +26.5% revenue growth was magnified by accounting presentation. A fivefold outcome over ten years needs sustained growth in real service revenue, not a continued rise in zero-margin pass-through mix.

The third gate is capital allocation. MEDP's past fivefold/tenfold story came largely from high ROIC, negative working capital, strong FCF, and a share count that fell from about 40-41M after the IPO to about 28.56M today. But a current negative signal is that FY2025 repurchases were still aggressive, while Q4'25 and Q1'26 repurchases were $0, even though the current price still implies about 26x forward PE. If future repurchases happen at high prices and stop at low prices, EPS compounding will be meaningfully discounted.

Today's share price does not embed that "a fivefold gain over ten years is already certain." It embeds the market's continued belief that MEDP is a high-quality CRO, that FY2026 guidance can be delivered, that order deterioration is temporary, and that the company still deserves a growth-stock premium. The current price of $454.25 is roughly at the upper end of the report's base range of $380-460, while the average sell-side target is only about $443 and consensus is Hold (StockAnalysis forecast). In other words, the current price already pays for "quality + cyclical recovery," but leaves little margin of safety for "book-to-bill staying below 1, growth slowing to single digits, and PE compressing to 15-20x."

So the honest Q9 answer is: a ten-year fivefold gain is not impossible, but it is not a high-confidence fivefold stock today. It requires MEDP to recover quickly from the 2026 order trough and continue the same high-quality compounding at a larger scale; based on Q1'26 leading indicators, that is more a bull case than a base case.

Jun 6, 2026
Why has the market not recognized all of this yet? Is it because the market does not understand, underestimates it, or cannot look far enough? What will become the "narrative inflection point"?3/10

Conclusion: the market does not "fail to understand" Medpace's quality. It has already assigned a good-business valuation, but is not yet willing to assign a "fivefold in ten years" narrative valuation. The current price of $454.25 already corresponds to a market cap of about $12.97B, 28.6x trailing PE / about 26x forward PE; sell-side consensus is only Hold, with an average target price of $442.83, essentially right around the current price. This shows the market is not dismissing its ROIC, net cash, founder ownership, or long-term compounding, but is asking for the next set of evidence: is the order cycle a temporary hole, or has the growth center of gravity moved lower?

The real perception gap is "cyclical lag," not "nobody understands the business model." The bull narrative is that small and mid-sized biotech funding recovered in 2025H2/2026 and typically takes 12-15 months to flow through to CRO bookings; if that chain is correct, Medpace's current book-to-bill trough is the entry window. But bears also have hard evidence: net book-to-bill has slid from 1.20x(Q3'25) to 1.04x(Q4'25), then to 0.88x in Q1'26; the company's Q1'26 10-Q disclosed net new awards of $618.4M and backlog of $2.9292B, while management acknowledged on the call that RFPs were down sequentially and year over year, cancellations were at a more than one-year high, and sequential growth over the next six months is a real issue. Given this evidence mix, the market's choice to "not look far enough" has a rational basis.

The narrative inflection points will be very specific: first, book-to-bill in Q2/Q3 returning above 1.0x in any quarter, and not because of a low revenue denominator or accounting presentation, but alongside simultaneous improvement in gross awards, RFP quality, and cancellations; second, backlog returning to sequential growth, allowing the market to see FY2027 revenue as more than high single digit to low double digit growth; third, metabolic/GLP-1 projects continuing to show low cancellation rates, proving that FY2025 metabolic revenue growth of +62.8% and 29.4% share was not a one-off boom; fourth, the company restarting repurchases, especially after having about $821.7M of authorization remaining and zero repurchases in Q4'25 and Q1'26, which would be more persuasive than verbal confidence.

Conversely, if Q2/Q3 continue to show book-to-bill <1.0 and backlog erosion, or if preliminary FY2027 guidance lands at low-single-digit growth, the market will not suddenly "recognize greatness"; it will reprice the company from a high-quality growth stock into a high-quality cyclical stock. Under the Baillie framework, MEDP's perception gap is not "the market missed an obvious fivefold stock," but "the market has not yet dared to believe that a funding recovery will cut through cancellations, pass-through cost noise, and the litigation shadow." There is only one core narrative inflection point: leading order indicators must prove that the growth engine is still running.

Jun 6, 2026

Ask about this report

Members can ask about this report; once answered it appears under "Reader Q&A" on this page. You can also highlight a passage in the text to ask about it directly.